Bromoacetamido-PEG2-C2-acid

Cat. No.: HY-141380

CAS No.: 1415800-44-0

Molecular Formula: $C_9H_{16}BrNO_5$

Molecular Weight: 298.13

Target: PROTAC Linkers

Pathway: PROTAC

Storage:

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (335.42 mM; Need ultrasonic)

Preparing Stock Solutions

Solvent / Mass / Concentration	1 mg	5 mg	10 mg
1 mM	3.3542 mL	16.7712 mL	33.5424 mL
5 mM	0.6708 mL	3.3542 mL	6.7085 mL
10 mM	0.3354 mL	1.6771 mL	3.3542 mL

Please refer to the solubility information to select the appropriate solvent.

In Vivo

1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline
   Solubility: ≥ 2.5 mg/mL (8.39 mM); Clear solution
2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)
   Solubility: ≥ 2.5 mg/mL (8.39 mM); Clear solution
3. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: ≥ 2.5 mg/mL (8.39 mM); Clear solution

BIOLOGICAL ACTIVITY

Description

Bromoacetamido-PEG2-C2-acid is a PEG-based PROTAC linker that can be used in the synthesis of PROTACs[1].

IC_{50} & Target

PEGs

In Vitro

PROTACs contain two different ligands connected by a linker; one is a ligand for an E3 ubiquitin ligase and the other is for the target protein. PROTACs exploit the intracellular ubiquitin-proteasome system to selectively degrade target proteins[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA